Additional file 8: of Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

Table S7. References used to derive monthly mortality of patients with compensated cirrhosis and progressive HCC after TACE. (DOCX 13 kb)